JP2025501913A - 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用 - Google Patents

血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用 Download PDF

Info

Publication number
JP2025501913A
JP2025501913A JP2024538390A JP2024538390A JP2025501913A JP 2025501913 A JP2025501913 A JP 2025501913A JP 2024538390 A JP2024538390 A JP 2024538390A JP 2024538390 A JP2024538390 A JP 2024538390A JP 2025501913 A JP2025501913 A JP 2025501913A
Authority
JP
Japan
Prior art keywords
seq
variable region
fusion protein
chain variable
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501913A5 (cg-RX-API-DMAC10.html
Inventor
ウ ドゥム チュン，
スミン リュ，
ドンゴン キム，
ジフン チャン，
ビョン チュル リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanaph Therapeutics Inc
Original Assignee
Kanaph Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanaph Therapeutics Inc filed Critical Kanaph Therapeutics Inc
Publication of JP2025501913A publication Critical patent/JP2025501913A/ja
Publication of JP2025501913A5 publication Critical patent/JP2025501913A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024538390A 2022-01-05 2022-12-27 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用 Pending JP2025501913A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020220001647A KR20230105972A (ko) 2022-01-05 2022-01-05 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
KR10-2022-0001647 2022-01-05
PCT/KR2022/021371 WO2023132547A1 (ko) 2022-01-05 2022-12-27 혈관신생 억제제가 결합된 항-c3b 항체 또는 항-c5 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
JP2025501913A true JP2025501913A (ja) 2025-01-24
JP2025501913A5 JP2025501913A5 (cg-RX-API-DMAC10.html) 2025-12-02

Family

ID=87073766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538390A Pending JP2025501913A (ja) 2022-01-05 2022-12-27 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用

Country Status (7)

Country Link
US (1) US20250074974A1 (cg-RX-API-DMAC10.html)
EP (1) EP4461745A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025501913A (cg-RX-API-DMAC10.html)
KR (1) KR20230105972A (cg-RX-API-DMAC10.html)
CN (1) CN118510799A (cg-RX-API-DMAC10.html)
AU (1) AU2022430428A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023132547A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7560185B2 (ja) * 2020-07-07 2024-10-02 カナプ セラピューティクス インコーポレイテッド 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4897690B2 (ja) 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
HUE066795T2 (hu) * 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
AU2008262048B2 (en) * 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
EP3600442A1 (en) * 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
US20190167790A1 (en) 2017-12-05 2019-06-06 Abbvie Biotherapeutics Inc. Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
JP2022512657A (ja) * 2018-10-12 2022-02-07 トリカン・バイオテクノロジー・カンパニー・リミテッド 二機能性融合タンパク質およびその使用
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION

Also Published As

Publication number Publication date
EP4461745A1 (en) 2024-11-13
KR20230105972A (ko) 2023-07-12
CN118510799A (zh) 2024-08-16
US20250074974A1 (en) 2025-03-06
EP4461745A4 (en) 2025-07-02
WO2023132547A1 (ko) 2023-07-13
AU2022430428A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
JP6194302B2 (ja) 血管新生および周皮細胞組成物を調節するための方法および組成物
CN117467025B (zh) 一种抗vegf和补体双功能融合蛋白及其应用
CN104159926B (zh) 补体和vegf途径的蛋白质抑制剂及其使用方法
JP2012528112A (ja) 抗原結合タンパク質
TW200904471A (en) Prevention and the treatment of complement-associated eye conditions
CN109415435B (zh) 新型抗体形式
CN112262158B (zh) 新型血管生成素2，vegf双特异性拮抗剂
WO2024125180A1 (zh) 抗cd155的抗体及其应用
EP4461745A1 (en) Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof
JP7560185B2 (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
US20250051460A1 (en) Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
KR20220029524A (ko) 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
HK40110067A (en) Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof
KR20220147787A (ko) 보체 경로 억제 단백질을 포함하는 융합단백질 및 이의 용도
TW202019476A (zh) 伴隨視網膜纖維化之眼部疾病之藥劑
WO2024114641A1 (en) C5/vegf bispecific binding molecules
CN115850470B (zh) Vegf抗体及其应用
HK40126782A (en) C5/vegf bispecific binding molecules
KR20250128899A (ko) Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
TW202530256A (zh) 多特異性抗原結合多肽之組合物及使用方法
KR20220029343A (ko) 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251121